Enhanced Fatty Acid Synthesis Leads to Subset Imbalance and IFN-γ Overproduction in T Helper 1 Cells

Shigeru Iwata1, Mingzeng Zhang1,2, He Hao1,3, Gulzhan Trimova1,4, Maiko Hajime1, Yusuke Miyazaki1, Naoaki Ohkubo1, Yurie Satoh Kanda1, Yasuyuki Todoroki1, Hiroko Miyata1, Masanobu Ueno1, Atsushi Nagayasu1, Shingo Nakayamada1, Kei Sakata1,5 and Yoshiya Tanaka1*

1 The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Kitakyushu, Japan, 2 Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, 3 Department of Immuno-oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, 4 Department of Clinical Subjects, High School of Medicine, Faculty of Medicine and Health Care, Al-Farabi Kazakh National University, Almaty, Kazakhstan, 5 Research Unit/Immunology & Inflammation, Innovative Research Division, Mitsubishi Tanabe Pharma, Yokohama, Japan

Recent reports have shown the importance of IFN-γ and T-bet+ B cells in the pathology of SLE, suggesting the involvement of IFN-γ-producing T-bet+ CD4+ cells, i.e., Th1 cells. This study determined the changes in Th1 subsets with metabolic shift and their potential as therapeutic targets in SLE. Compared with healthy donors, patients with SLE had higher numbers of T-bethiCXCR3lo effector cells and T-bet+Foxp3lo non-suppressive cells, which excessively produce IFN-γ, and lower number of non-IFN-γ-producing T-bet+Foxp3hi activated-Treg cells. These changes were considered to be involved in treatment resistance. The differentiation mechanism of Th1 subsets was investigated in vitro using memory CD4+ cells obtained from healthy donors and patients with SLE. In memory CD4+ cells of healthy donors, both rapamycin and 2-deoxy-D-glucose (2DG) suppressed T-bet+Foxp3- cells, and induced T-bet +Foxp3+(lo/hi) cells. Rapamycin induced IFN-γ-producing T-bet+Foxp3lo cells accompanied with enhanced lipid metabolism, whereas 2DG induced IFN-γ-non-producing T-bet+Foxp3hi cells. In memory CD4+ cells of SLE patients, inhibition of fatty acid synthesis, but not β-oxidation, suppressed IFN-γ production, and up-regulated of Foxp3 expression in T-bet+Foxp3+ cells. Metabolic regulators such as fatty acid synthesis inhibitors may improve the pathological status by correcting Th1 subset imbalance and overproduction of IFN-γ in SLE.

Keywords: systemic lupus erythematosus, T-bet, IFN-γ, fatty acid synthesis, immunometabolism

INTRODUCTION

Systemic lupus erythematosus (SLE) is a common autoimmune disease. That nonspecific treatment of steroids or immunosuppressants is still used as the main therapeutic modality stresses the need to explore the pathological mechanisms and design new therapeutic strategies for SLE.

IFN signature plays an important role in SLE (1). In recent years, modular transcriptional repertoire analysis has demonstrated a different type I/II IFN signature and the importance of not only type I IFN...
but also type II IFN (IFN-γ) (2). While helper T (Th) cells are known to play an important role in the pathogenesis of SLE, their differentiation and functional abnormalities remain unclear (3).

In the 1990–2010, SLE pathology was discussed in the context of a balance between Th1 and Th2, together with the involvement of Th1 (4, 5). However, Th1 is only defined as an IFN-γ-producing cell, and other important markers for Th1 such as CXCR3 and T-bet, have not been simultaneously examined in these papers. Recently, the diversity of Th cells has been reported, and CXCR3, T-bet and IFN-γ have been reported to be expressed not only in Th1 but also in other diverse Th subsets. In particular, it was reported that T peripheral helper (TPH) cells not only in Th1 but also in other diverse Th subsets. In particular, it was reported that T peripheral helper (TPH) cells.

Recent studies have emphasized the roles of T-bet+ B cells for B cell help, produced IFN-γ and Th10 cells, which attract much attention and are important, particularly, it was reported that T peripheral helper (TPH) cells not only in Th1 but also in other diverse Th subsets. In particular, it was reported that T peripheral helper (TPH) cells.

TPH cells and Th10 cells, which attract much attention and are important for B cell help, produced IFN-γ and expressed CXCR3 and T-bet (6, 7). Recent studies have emphasized the roles of T-bet⁺ B cells in SLE pathology, such as the production of autoantibodies and renal involvement (8–11). TPH cells and Th10 cells were known to be correlated with T-bet⁺ B cells in SLE (6, 12).

T-bet is known as a master transcription factor that regulates Th1 differentiation, and it was reported previously that T-bet plays a positive role in the regulation of IFN-γ production by effector Th1 cells (13, 14). Interestingly, various new functions of T-bet as a transcription factor have been recognized in recent years, including the presence of T-bet⁺Foxp3⁺ Treg, which specifically inhibits Th1 in mice (15) and inhibition of aberrant autocrine type I IFN and its downstream signaling in Th1 (16). However, the role of T-bet-expressing CD4⁺ cells, i.e., Th1 subsets, in SLE pathology remains unknown.

During the process of tissue infection, lymphocytes, including Th cells, rapidly change into the effector phase upon antigen stimulation. These activities require massive energy and rapid synthesis of biological components using amino acids, lipids, and nucleic acids (17). Recent studies in rodents have demonstrated enhanced glycolysis under aerobic conditions associated with such anabolic processes in the activation of various immunocytes (18–21). The differentiation regulation mechanism through immunometabolism involved in Th cell differentiation is being clarified in many studies mainly in mice; however, it is largely unknown in human, particularly in the pathology of autoimmune diseases, such as SLE.

The aim of this study was to shed light on the pathogenic process of SLE. Specifically, we determined the changes in Th1 subsets in SLE patients and the roles of these cells in the differentiation regulation mechanism via immunometabolism.

**MATERIALS AND METHODS**

**Cell Isolation and Differentiation**

Peripheral blood mononuclear cells (PBMCs) were isolated from healthy adults using lymphocyte separation medium (Lympholyte-H; Cedarlane, Burlington, NC), and CD4⁺ T cells were purified by negative selection using CD4⁺ T cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany) and magnetic separation (Miltenyi Biotec) for negative selection CD45RA⁺ memory T cells were further purified by negative selection using MACS Naive CD4⁺ T cell isolation kit (Miltenyi Biotec). We confirmed that the purity of the obtained CD45RA⁺ memory CD4⁺ T cells was higher than 90%, as determined by flow cytometric analysis. CD45RA⁻ memory CD4⁺ T cells were activated by plate-bound anti-CD3 (2 μg/ml; eBioscience) and anti-CD28 (0.5 μg/ml; eBioscience) with anti-IFNγR Abs (10 μg/ml; R&D Systems, Inc.), tofacitinib (JAK inhibitor) (300 nM, kindly provided by Pfizer), rapamycin (mTORC1 inhibitor) (10 nM, Selleck Chemicals, Houston, TX), or 2-DG (3 mM, Wako Pure Chemical Industries, Osaka, Japan), C75 (racemic) (10 μM; Sigma Aldrich) cultured for 3 days in RPMI-1640 (Wako Pure Chemical Industries) supplemented with 10% FCS (Tissue Culture Biologicals, Tulare, CA), 100 U/ml penicillin and 100 U/ml streptomycin (Thermo Fisher Scientific, Carlsbad, CA).

**Patients**

PBMCs were obtained from patients with SLE and healthy subjects. The clinical characteristics of the patients are summarized in Table 1.

**Flow Cytometry**

After washing the cells (PBMCs or CD4⁺CD45RA⁻ T cells), they were suspended in 100 ml of FACS solution (0.5% human albumin and 0.1% NaN₃ in PBS) and stained with the following antibodies: V500-conjugated anti-CD4 (BD, #560047), PerCP-Cy5.5-conjugated anti-CD25 (BD, #560503), FITC-conjugated anti-CD28 (BD, #555728), PerCP-Cy5.5-conjugated anti-CXCR3 (BD, #580832), FITC-conjugated anti-CD38 (BD, #555459), and V500-conjugated anti-CD4 (BD, #560769). Then, intracellular staining, PBMCs were cultured for 3 days in RPMI-1640 supplemented with 10% FCS (Tissue Culture Biologicals, Tulare, CA), 100 U/ml penicillin and 100 U/ml streptomycin (Thermo Fisher Scientific, Carlsbad, CA).

**Lactate Assay**

CD45RA⁺ memory CD4⁺ T cells were cultured alone or under stimulation/treatment for 3 days in 96-well plates. The culture medium was later collected and diluted properly for measurement of lactate concentration using Lactate Assay Kit II (BioVision, Milpitas, CA). Isotype-matched mouse IgG controls (BD, #560047, BD PharMingen), mTOR (pS2448) (#O21-404) (PE)-conjugated labeled, #563489, BD PharMingen), IFN-γ (APC)-conjugated labeled, #554702, BD PharMingen), PBMCs were fixed and permeabilized with Perm Buffer III (BD Phosflow™) or Transcription Factor Buffer Set (BD Biosciences) before intracellular staining, then analyzed on FACSVersa (BD Biosciences). Isotype-matched mouse IgG controls (BD, Phosflow) were used to evaluate the background. Finally, the cells were washed three times with FACS solution and analyzed with a FACSVersa (BD, San Jose, CA) and FlowJo software (Tomy Digital Biology, Tokyo). For IFN-γ staining, PBMCs were incubated with PMA (50 nG/ml, 1544-5, Wako), ionomycin (1 μg/ml, Sigma Aldrich, MO) and brefeldin (2.5 μg/ml, B7651, SIGMA-Aldrich) for 1 h at 37°C.
TABLE 1 | Baseline characteristics of the study subjects.

| SLE (n = 60) | HD (n = 31) | p-value |
|--------------|-------------|---------|
| Age, years   | 41.4 ± 13.6 | 44.0 ± 19.3 | 0.8735 |
| Gender       | M:F 5:55    | M:F 5:26  | 0.1366 |
| Disease duration, months | 142.3 ± 123.6 | 40/60 |
| Corticosteroid use | 11.5 ± 9.0 | 12.9 ± 11.0 |
| SLEDAI score | 8.9 ± 10.8  | 10.5 ± 12.1 | 0.7894 |
| BILAG score  | 10.5 ± 12.1 | 12.9 ± 11.0 | 0.7894 |
| clinical relevant organ involvement (BILAG A or B) | 24/60 (40.0%) | 36/60 |
| constitutional | 24/60 (40.0%) | 26/60 (43.3%) |
| mucocutaneous | 14/60 (23.3%) | 4/60 (6.7%) |
| central nervous system | 4/60 (6.7%) | 20/60 (33.3%) |
| acute cutaneous state | 4/60 (6.7%) | 1/60 (1.7%) |
| cerebrovascular disease | 4/60 (6.7%) | 1/60 (1.7%) |
| seizure disorders | 2/60 (3.3%) | 2/60 (3.3%) |
| headache | 2/60 (3.3%) | 2/60 (3.3%) |
| mood disorder | 2/60 (3.3%) | 2/60 (3.3%) |
| cognitive dysfunction | 1/60 (1.7%) | 1/60 (1.7%) |
| aseptic meningitis | 1/60 (1.7%) | 1/60 (1.7%) |
| neutropathy | 1/60 (1.7%) | 1/60 (1.7%) |
| musculoskeletal | 10/60 (16.7%) | 6/60 (19.4%) |
| cardiovascular/respiratory | 2/60 (3.3%) | 2/60 (3.3%) |
| abdominal | 4/60 (6.7%) | 2/60 (6.7%) |
| renal | 20/60 (33.3%) | 15/60 (25.0%) |
| ophthalmic | 0/60 (0%) | 1/60 (1.7%) |
| haematological | 20/60 (33.3%) | 15/60 (25.0%) |
| anti-dsDNA Abs (IU/ml) | 76.6 ± 124.9 | 76.6 ± 124.9 |
| anti-Sm Abs (IU/ml) | 40.4 ± 137.2 | 40.4 ± 137.2 |
| history of treatment | 1.5 ± 1.6 | 1.5 ± 1.6 |
| immunosuppressants | 1.5 ± 1.6 | 1.5 ± 1.6 |
| IVCY | 10 | 10 |
| AZ | 15 | 15 |
| TAC | 15 | 15 |
| CsA | 10 | 10 |
| MTX | 8 | 8 |
| MZ | 5 | 5 |
| RTX | 2 | 2 |
| hCQ | 1 | 1 |
| ABT | 3 | 3 |
| MMF | 1 | 1 |
| High-dose corticosteroid (times) | 0.8 ± 0.8 | 0.8 ± 0.8 |
| Steroid pulse (times) | 0.5 ± 1.3 | 0.5 ± 1.3 |

Data are mean ± SD or number of patients.

See Table 1 for abbreviations. IVCY, intravenous cyclophosphamide; AZ, azathioprine; TAC, tacrolimus; CsA, cyclosporin; MTX, methotrexate; MZ, mizoribine; RTX, rituximab; hCQ, Hydroxychloroquine; ABT, abatacept; MMF, mycophenolate mofetil. High-dose corticosteroids were defined as the equivalent of prednisolone ≥0.8 mg/kg/day. Low-dose corticosteroids were defined as the equivalent of prednisolone ≤1 mg/day.

Intracellular ROS Levels

After 3-day culture, CD45RA- memory CD4+ T cells were gently washed twice with 37°C PBS, then incubated with 100 µl of 1X DCFH-DA medium solution at 37°C for 60 min. They were repeatedly washed thereafter with PBS at 37°C, then cultured for 5 min in wells each containing 100 µl of culture medium with 100 µl of 2X Cell Lysis Buffer. Finally, 150 µl of the culture mixture was transferred to a 96-well plate black culture fluorometric plates. Fluorescence was read with a fluorometric plate reader at 480/530 nm.

Quantitative Real-Time PCR

Total RNA was prepared by using the RNeasy Mini Kit (Qiagen, Chatsworth, CA). First-strand cDNA was synthesized, and quantitative real-time PCR was performed in the Step One Plus instrument (Applied Biosystems, Foster City, CA) in triplicate wells of 96-well plates. TaqMan target mixes for Enhancer of Zeste homolog 2 (EZH2) (Hs00544830_m1), basic leucine zipper transcription factor 2 (BACH2) (Hs00222364_m1), interferon regulatory factor 4 (IRF4) (Hs01056533_m1), PR domain containing 1 (PRDM1) (Hs00153357_m1), carnitine palmitoyltransferase IA (CPTIA) (Hs00912671_m1), carnitine palmitoyltransferase II (CPT2) (Hs00988962_m1), fatty acid synthase (FASN) (Hs0105622_m1), sterol regulatory element-binding transcription factor 1 (SREBF1) (Hs01088679_g1), were purchased from Applied Biosystems. The mRNA expression level was normalized to the level of the endogenous control (GAPDH ribosomal RNA, #Hs99999905-m1, Applied Biosystems), and the relative quantity, compared with the PBMC sample as a reference, was calculated by using the quantification-comparative cycle threshold (DDCT) formula. The relative quantity was calculated by using the DDCT formula—referenced sample of PBMCs.

Extracellular Flux Analysis

The XF96 Extracellular Flux analyzer (Seahorse Biosciences, North Billerica, MA) was used to quantify the oxygen consumption rate (OCR). CD45RA- memory CD4+ T cells stimulated for 3 days were resuspended in XF media and then plated on XF96 cell culture microplates (2 × 10^5 cells per well) coated with Cell-Tak (BD Biosciences). The OCR was measured in XF media (Agilent Technologies, Santa Clara, CA) supplemented with 1 mM sodium pyruvate, 10 mM glucose, and 2 mM L-glutamine under both basal conditions and in following the addition of 2 µM oligomycin, 2 µM carbonyl cyanide-p-trifluoromethoxy-phenylhydrazone (FCCP), and rotenone/antimycin A (Rot/AA).

Electron Microscopy

Cells were collected and immersed in 2% glutaraldehyde solution at 4°C for 4 h. The samples were washed three times with 1 mol/L phosphate buffer, followed by 1% osmium tetroxide for 2 h, dehydrated in graded concentrations of alcohol (50, 70, 80, 90, and 100%), and embedded in epoxy resin. The embedded samples were then cut into ultra-thin serial sections (80 nm, Ultramicrotome, Leica UC-7, Leica, Germany) and stained with lead citrate and uranyl acetate. The samples were subsequently visualized using an electron microscope (JEOL, JEM-1200EX, Japan) at 80 kV at the Department of Electron Microscopy Center of University of Occupational & Environmental Health.

Gas Chromatography Mass Spectrometry

2×10^6 CD45RA-CD4+ T cells metabolome under different conditions were extracted with 50% acetonitrile-water. Dried powder was dissolved in 20 mg/ml pyridine in methoxylamine-HCl, followed
by N-Methyl-N- (trimethylsilyl) trifluoro-acetamide (MSTFA) reagent. The metabolome was identified using GC/MS (JMS-Q1500, 7890GC, JEOL, Japan) equipped with a direct capillary column DB-5MS sized 30 m×0.25 mm×0.25 μm film thickness. The column temperature was set at 80°C for 2 min and gradually increased at 15°C/min until it reached 320°C then held for 12 min. The temperature of the injector was adjusted to 230°C and the MS transfer line was adjusted to 250°C. Helium gas was used as the carrier gas, which was injected at a constant flow rate of 1.5 ml/min. In the next step, 1 μl of the sample was injected with a solvent delay at 2 min. An autosampler (7650A) was coupled with the GC and set in split mode for automatic injection of the samples and solvents. The effluent of GC column was transferred directly into the source of the MS through the transfer line. Electron ionization mass spectrometry fragments were initiated at 70 eV within the range of 30–500 m/z at a full scan mode. The temperature of the ion source was adjusted to 200°C. NIST mass spectral libraries were used to identify the obtained mass spectra of the active molecules in the extract.

**Statistical Analysis**

All data were expressed as mean ± SD, unless otherwise indicated. Differences between groups were examined for statistical significance by the paired- or unpaired-t test. Pearson correlation coefficient was used to test the relation between two variables of interest. A p-value of <0.05 denoted the presence of statistical significance. Statistical analyses were conducted using the Prism software (Prism Software, Irvine, CA).

**RESULTS**

**Accumulation of IFN-γ Producing-CXCR3loT-bethi Effector Memory CD4+ Cells in SLE**

First, we used T-bet, CXCR3, and IFN-γ, which are originally known as typical markers of Th1 cells, to examine possible abnormalities of Th1 cells in the peripheral blood of SLE patients. Table 1 summarizes the clinical background of the Japanese 60 participating patients. They included 5 males and 55 females, with a mean disease duration of 142 months, SLEDAS of 11.5 ± 9.0, BILAG 12.9 ± 11.0, clinical relevant organ involvement (lupus nephritis 33.3%, central nervous system 23.3%). We also enrolled 31 age- and gender-matched healthy donors (the control group) (Table 1).

CD4+ T cells were separated into three populations of CXCR3- T-bet-, CXCR3hiT-betlo, and CXCR3loT-bethi cells. The percentage of CXCR3loT-bethi cells among CD4+ T cells was significantly higher in SLE than the control (HD: 1.9 ± 2.8%, SLE: 5.6 ± 8.5%) (Figure 1A). CXCR3 ‘T-bet’ cells mainly consisted of CCR7+CD45RA- naïve cells, CXCR3hiT-betlo cells consisted of CCR7-CD45RA+ central memory cells and CCR7-CD45RA- effector memory cells, and CXCR3loT-bet -cells consisted mainly of CCR7+CD45RA+ effector memory cells (Figure 1B). CXCR3loT-bethi cells which did not express CD28, were CXCR5 CCR6+ cells (Figures 1C, D). The percentage of HLA-DR+CD38+ cells among CD4+ T cells was significantly higher in SLE than the control. In addition, the percentage of HLA-DR+CD38+ cells among CD4+ T cells was significantly higher in CXCR3hiT-betlo cells than CXCR3- T-bet- and CXCR3loT-bet -cells in SLE (Figures 1E, F). CXCR3hiT-bet -lo cells were Foxp3+ cells (Figure 1G). CXCR3hiT-bethi cells showed high potential for IFN-γ production selectively in patients with SLE but not in the control (Figure 1H).

Next, we examined the relation of CXCR3loT-bet -hi cells to the clinical background of patients with SLE. The results showed that disease duration and treatment resistance were the parameter that significantly related to the percentage of CXCR3hiT-bet -hi cells (Figure 2).

**High IFN-γ Producing T-bet+Foxp3lo Non-Suppressive Cells and Low IFN-γ Non-Producing T-bet+Foxp3hi-Activated-Treg Cells Percentages in SLE**

Next, we analyzed the changes in T-bet+Foxp3+ cells in SLE patients. The clinical characteristics of the patients are summarized in Supplementary Table 1. For this purpose, peripheral blood Foxp3+ CD4+ T cells were divided to three subsets of CD45RA+Foxp3lo naïve-Treg, CD45RA Foxp3lo non-suppressive cells, and CD45RA Foxp3hi activated-Treg (22). There were no differences in the percentages of CD45RA+Foxp3lo naïve-Treg, CD45RA Foxp3hi activated-Treg between SLE and the control. However, the percentage of CD45RA Foxp3lo non-suppressive cells was significantly higher in SLE than the control (Figure 3A). Considering in detail of these populations, the percentage of IFN-γ producing-T-bet+ cells among CD45RA Foxp3lo non-suppressive cells was higher while the percentage of IFN-γ non-producing-T-bet+ cells among CD45RA Foxp3hi activated-Treg cells was lower in patients with SLE, compared to the control (Figures 3B, C). Activation of mTOR, which is known to induce various anabolic processes, such as aerobic glycolysis, is important in the maintenance of a balance between Treg and Teff differentiation (23). Phosphorylation of mTOR in peripheral CD4+ T cells of patients with SLE was significantly higher than the control. Phosphorylation of mTOR was significantly correlated with T-bet expression in CXCR3loT-bethi CD4+ T cells, but not in total CD4+ cells (Figure 3D). These results suggest that activation of mTOR can affect the imbalance between Th1 subsets.

**Rapamycin Induced IFN-γ Producing-T-bet+F oxp3lo Cells, Whereas 2DG Induced IFN-γ Non-Producing-T-bet+F oxp3hi Cells by Different Effects on Lipid Metabolism**

In the next step, we examined in vitro the effects of rapamycin, a mTORC1 inhibitor, and 2DG, a glycolysis inhibitor, on cell metabolism, differentiation, and function in stimulated memory CD4+ cells obtained from HDs, as only a few CD4+CD45RA memory T cells were obtained from the patients with SLE. Stimulation with anti-CD3 Abs and anti-CD28 Abs induced mTOR phosphorylation and T-bet expression selectively in CD45RA CD4+ memory cells (Figure 4A). The addition of rapamycin or 2DG reduced the percentage of CD4+CD25+Foxp3+ Treg cells and increased CD4+CD25+Foxp3hi Treg cells among CD45RA CD4+ cells, with a resultant significant increase in the
FIGURE 1 | High percentage of CXCR3loT-bethi effector memory CD4+ cells in patients with SLE. PBMCs were obtained from 31 healthy donors (HDs) and 60 SLE patients, and CD3+CD4+ T cells were gated. (A) Expression levels of T-bet and CXCR3 in CD4+ T cells were analyzed by intracellular staining using flow cytometry and shown in representative dot plots (left panel) and scatter plots of percentage of CXCR3loT-bethi cells (right panel). (B) CCR7 and CD45RA were double-stained in CD4+ T cells and gated in R1 (CXCR3-T-bet-), R2 (CXCR3hiT-betlo), and R3 (CXCR3loT-bethi) in CD4+ T cells in patients with SLE. (C) T-bet and CD28 in CD4+ T cells were double-stained in CD4+ T cells. Percentages of CXCR5+ cells in CD28+/-CD4+ cells and CCR6+ cells in CD28+/-CD4+ cells of SLE patients (n = 43) were shown in scatter plots. (E) Percentages of CD38HLA-DR+ among CD4+ T cells were analyzed for HDs and SLE patients by flow cytometry and shown in the scatter plots. (F) Representative dot plots (left) and scatter plots (right) of expression of CD38 and HLA-DR in R1, R2 and R3 in CD4+ T cells from patients with SLE. (G) Expression of T-bet and Foxp3 in CD4+ T cells from patients with SLE was shown in the representative dot plots. (H) Representative dot plots of expression of T-bet and IFN-γ in CD4+ cells in HDs and SLE patients were shown (left). Percentages of T-betIFN-γ cells among CD4+ T cells from HDs and SLE patients were shown in scatter plots (right). For T-bet and IFN-γ staining, PBMCs were incubated with PMA (50 ng/ml), ionomycin (1 μg/ml) and brefeldin (2.5 μg/ml) for 1 h at 37°C. *p < 0.05, **p < 0.001, ***p < 0.0001.
The Treg/Teff ratio (Supplemental Figure 1A). BACH2, IRF4, PRDM1, and EZH2 are transcriptional factors important for the differentiation and function of effector Treg cells (24–27). Both rapamycin and 2DG induced upregulation of BACH2, IRF4, PRDM1, and EZH2 in CD45RA-CD4+ cells (Supplemental Figure 1B). Evaluation of the changes in Th1, Th2, and Th17 cytokines demonstrated that rapamycin and 2DG had different effects on these cytokines, especially their effects on Th1 cytokines. For example, anti-CD3 Abs and anti-CD28 Abs-stimulated IFN-γ was more strongly inhibited by 2DG than by rapamycin. In contrast, interleukin (IL) 2 was not induced by anti-CD3 Abs and anti-CD28 Abs stimulation but strongly induced only by 2DG (Supplemental Figure 1C).

Next, we assessed the effects of rapamycin and 2DG on T-bet+Foxp3+ cells differentiation. Rapamycin induced IFN-γ-producing T-bet+Foxp3 cells. On the other hand, 2DG induced IFN-γ-non-producing T-bet+Foxp3 cells (Figures 4B, C). Both rapamycin-induced T-bet+Foxp3 cells and 2DG-induced T-bet+Foxp3 cells produced IL-10, and the production tended to be slightly larger in the latter (Figure 4D). Since rapamycin and 2DG have different effects on T-bet+Foxp3 cell differentiation, we next examined the mechanism from the perspective of cell metabolism using CD4+CD45RA- memory T cells obtained from HDs. Although rapamycin and 2DG had similar effects on the dynamics of cellular metabolism, such as aerobic glycolysis, mitochondrial function and glutaminolysis (Supplemental Figures 2, 3), their effect on lipid metabolism was different. The expression levels of fatty acid oxidation-related enzymes such as CPT1a and CPT2 were increased by both rapamycin and 2DG, while the expression levels of fatty acid synthesis-related enzymes such as FASN and SREBF1 were more highly increased by rapamycin compared with 2DG. This effect of rapamycin was coupled with larger increases in palmitic and stearic acid levels compared with 2DG, suggestive of enhancement of lipid metabolism, selectively in fatty acid synthesis (Figures 4E–G). These results indicate that rapamycin, but not 2DG, enhanced lipid metabolism, resulting in distinct effect in T-bet+Foxp3+ cell differentiation and its IFN-γ production.

Inhibition of Fatty Acid Synthesis in Memory CD4+ Cells Obtained From SLE Patients Resulted in Suppression of IFN-γ Production and Up-Regulated Foxp3 Expression in T-bet+Foxp3+ Cells

We also investigated the role of dyslipidemia in the observed changes in T-bet+Foxp3+ cell differentiation and IFN-γ production by memory CD4+ T cells of HDs and SLE patients. The results showed that stimulation of the memory CD4+ T cells with anti-CD3 Abs and anti-CD28 Abs induced IFN-γ-producing...
FIGURE 3 | IFN-γ producing-T-bet+Foxp3lo non-suppressive cells were increased, whereas IFN-γ nonproducing-T-bet+Foxp3hi activated-Treg cells were decreased in patients with SLE. PBMCs were obtained from 16 HDs and 18 SLE patients, and CD3+CD4+ T cells were gated. (A) Expression of Foxp3 and CD45RA in CD4+ T cells were analyzed by intracellular staining using flow cytometry and shown in the representative dot plots (left panels) and scatter plots of percentage of CD45RA+Foxp3lo cells (naïve-Treg), CD45RA-Foxp3lo cells (non-suppressive cells), and CD45RA-Foxp3hi cells (activated-Treg) (right panels). (B) Double-staining of T-bet and IFN-γ expression in CD4+ T cells and gated in CD45RA+Foxp3lo cells (naïve-Treg), CD45RA Foxp3lo cells (non-suppressive cells) and CD45RA Foxp3hi cells (activated-Treg) in HDs and SLE patients. Data are representative dot plots (left panels) and scatter plots of percentage of T-bet+IFNγ+ cells among Foxp3loCD45RA-CD4+ cells (right panel). (C) Double-staining of T-bet and CXCR3 expression in CD4+ T cells and gated in CD45RA+Foxp3hi cells (activated-Treg) in HDs and SLE patients. Data are representative dot plots (left panels) and scatter plots of percentage of CXCR3+ cells among CD4+CD45RA-Foxp3hi cells (right panel). (D) The ΔMFI/isotype MFI of mTOR phosphorylation in CD4+ T cells from HDs and SLE patients was analyzed by flow cytometry and shown in the scatter plots. Right panel: Correlation between ΔT-bet/isotype MFI and Δp-mTOR/isotype MFI in CD4+ T cells and CD4+CXCR3loT-bethi cells from SLE patients. Data are mean ± SD. Data are mean ± SD. *p < 0.05. ****p < 0.0001. n.s., not significant.
FIGURE 4 | Rapamycin induced IFN-γ producing-T-bet+Foxp3<sup>+</sup> cells, whereas 2DG induced IFN-γ nonproducing-T-bet+Foxp3<sup>+</sup> cells by different effects on fatty acid metabolism. CD45RA<sup>+</sup> naïve and CD45RA<sup>-</sup> memory CD4<sup>+</sup> T cells from peripheral blood of healthy donors were stimulated with anti-CD3 Abs and anti-CD28 Abs or rapamycin (10 nM) or 2DG (3 mM) for 72 h. (A) Representative results of mTOR phosphorylation and T-bet expression measured by intracellular staining and flow cytometry. (B) Upper panel; Expression of Foxp3 and T-bet in CD45RA<sup>+</sup> memory CD4<sup>+</sup> T cells after anti-CD3 Abs and anti-CD28 Abs stimulation with or without agents for 72 h. Lower panel; Foxp3 expression in gated regions (Left: T-bet-Foxp3<sup>+</sup> cells in no stimulation or anti-CD3 Abs and anti-CD28 Abs stimulation, Middle: T-bet-Foxp3<sup>+</sup> cells in anti-CD3 Abs and anti-CD28 Abs stimulation or with rapamycin or 2DG, Right: T-bet<sup>-</sup>Foxp3<sup>+</sup> cells in anti-CD3 Abs and anti-CD28 Abs stimulation or with rapamycin or 2DG). (C) Data are representative results of Foxp3 and IFN-γ expression (further treated with PMA, ionomycin and Brefeldin for 1 h) estimated by intracellular staining (left panel) and bar graph of the percentage of IFN-γ<sup>+</sup>Foxp3<sup>+</sup> cells (right panel). Pooled data (mean ± SD of MFI) of three independent experiments in (A–D). (E) The concentrations of glycerol, palmitic acid and stearic acid were measured by GC/MS. GC/MS data are mean ± SD of five independent experiments using cells from different healthy donors. (F, G) FASN, CPT1A, CPT2 and SREBF1 gene expression levels were determined by RT-PCR. These data are mean ± SD of four independent experiments using cells from different donors were shown. Data are mean ± SD. *p < 0.05. **p < 0.01. n.s., not significant.
T-bet Foxp3^+ cells in SLE samples (Figure 5A). Furthermore, the addition of rapamycin increased IFN-γ-producing T-bet Foxp3^+ cells in HDs cells. However, unlike the results in HDs cells, IFN-γ-producing T-bet Foxp3^+ cells remained unchanged by the addition of rapamycin in SLE patients (Figures 5B, C). Moreover, IFN-γ-producing T-bet Foxp3^+ cells did not change following the addition to rapamycin of etomoxir, a fatty acid β oxidation inhibitor, but was significantly inhibited by C75, a fatty acid synthesis inhibitor in both HDs and SLE patients (Figure 5B, Supplementary Figure 4A). The addition of C75 to rapamycin increased Foxp3 expression in T-bet Foxp3^+ cells to a level similar to that seen with 2DG (Figure 5C, Supplementary Figure 4B).

Finally, we evaluated the effects of various metabolic regulators on the production of IFN-γ and IL-2, which are two Th1 cytokines produced by memory CD4^+ T cells in HDs and SLE. IFN-γ production induced by anti-CD3 Abs and anti-CD28 Abs stimulation was inhibited by rapamycin and 2DG and further inhibited by the combination of C75 plus rapamycin in both HDs and SLE patients (Figure 5D, Supplementary Figure 4C). Interestingly, 2DG, but not anti-CD3 Abs and anti-CD28 Abs stimulation, induced IL-2 production in both HDs and SLE patients (Figure 5D).

**DISCUSSION**

We investigated the changes in Th1 subsets in SLE and their involvement in SLE pathology. Our results showed abundance of T-bet^{hi}CXCR3^{lo} effector cells and T-bet Foxp3^{lo} non-suppressive cells (which produce large amounts of IFN-γ) in SLE, compared with deficiency of T-bet Foxp3^{hi} activated T_{reg} cells (which do not produce IFN-γ). These changes were considered to be involved in treatment resistance. In the in vitro arm of the study, we showed that treatment of stimulated memory CD4^+ T cells with rapamycin and 2DG resulted in suppression of T-bet Foxp3^+ cells and induction of T-bet Foxp3^{lo}(Foxp3hi) cells. Interestingly, rapamycin alone enhanced lipid metabolism and induced IFN-γ-producing T-bet Foxp3^{lo} cells, whereas 2DG induced IFN-γ-non-producing T-bet Foxp3^{lo} cells. In memory CD4^+ cells of SLE patients, inhibition of fatty acid synthesis suppressed IFN-γ production and enhanced Foxp3 expression in T-bet Foxp3^+ cells. Thus, our results demonstrated that SLE is associated with IFN-γ overproduction by Th1 cells and Th1 subset imbalance due to metabolic abnormalities including enhanced fatty acid synthesis.

In the 1990–2010, SLE pathology was discussed in the context of a balance between Th1 and Th2, together with the involvement of Th1 (4, 5). However, Th1 is only defined as an IFN-γ-producing cell, and other important markers for Th1 such as CXCR3 and T-bet, have not been simultaneously examined in these papers. Recently, the diversity of Th cells has been reported, and CXCR3, T-bet, and IFN-γ have been reported to be expressed not only in Th1 but also in other diverse Th subsets. In particular, it was reported that TPH and Th10, which attract much attention and are important for B cell help, produced IFN-γ and expressed CXCR3 and T-bet (6, 7). In our study, the simultaneous confirmation of CXCR3, T-bet, and IFN-γ expression in CD4^+ cells revealed that CXCR3^{lo}T-bet^{hi} cells, rather than CXCR3^{hi}T-bet^{lo} cells, overproduced IFN-γ and was closely involved in the pathogenesis of SLE, including treatment resistance (Figures 1, 2). In addition, our results suggest that not only the aerobic glycolysis but also fatty acid synthesis may be involved in the subset imbalance and overproduction of IFN-γ in Th1 cells (Figure 5D).

In 2002, Gergely and colleagues (28) were the first to describe the metabolic changes in CD4^+ T cells in SLE, including increased mitochondrial membrane potential (hyperpolarization) and increased ROS production. Activation of mTORC1 in CD4^+ T cells has also been reported in a lupus mouse model as well as in SLE patients (29, 30), suggesting that differentiation to Th1 and Th17 is enhanced by mTORC1 in wild-type and autoimmune mice. Previous studies also discussed the importance of lipid metabolism in Th17 differentiation (31). Furthermore, various metabolic abnormalities have been described in CD4^+ T cells of SLE patients, but many aspects of SLE pathology remain unknown (32, 33). Our study highlighted the pathogenic roles of IFN-γ overproduction and imbalance of T-bet Foxp3 and T-bet Foxp3^+ cells, and that abnormal fatty acid synthesis is an important metabolic abnormality mediating the above changes.

The functional properties of mTORC1 include enhancement of mRNA translation, ribosome biogenesis, and glycolysis in the downstream, as well as inhibition of catabolic metabolism, such as autophagy, fatty acid oxidation, and oxidative phosphorylation in the mitochondria (34, 35). Rapamycin is known as an mTORC1 inhibitor whereas 2-deoxy-D-glucose (2DG) is a glycolysis inhibitor. Studies in experimental animals have demonstrated that mTORC1 activity and inhibition of aerobic glycolysis by rapamycin and 2DG are associated with suppression of T_{reg} cell and induction of T_{reg} cells (36–38). However, the effect of rapamycin and 2DG to human CD4^+ T cells, especially memory CD4^+ T cells remained unclear. In addition, there is no consensus on the role of mTORC1 in the induction of T_{reg} differentiation (39, 40). In related studies, it was demonstrated that T_{reg} cells induced by selective mTORC1 deficiency by deletion of TSC and phosphatase and tensin homolog (PTEN) and persistent activation, lacked immunosuppressive capacity (40, 41). Furthermore, mTORC1 deficient mice exhibited inhibition of T_{reg} induction, setting a series of inflammatory processes (42). Several studies reported that T-bet~ T_{reg} cells inhibit Th1 differentiation and Th1-related autoimmunopathologies (15, 43–46), while others indicated that these cells do not possess such suppressive activity (47). Thus, fractionation of (T-bet~) Foxp3^+ CD4^+ cells includes populations of plastic and non-functional or rather pro-inflammatory cells. It is suggested that rapamycin may promote the differentiation of these cells.

It has been reported that CD45RA Foxp3^{lo} non-suppressive T cells are increased in SLE patients and that these cells produce IFN-γ and IL-2 and exhibit little suppressive activity (48). On the other hand, CD45RA Foxp3^{hi} cells (activated-Treg) have not been found to be consistent (48, 49). In the present study, CD45RA Foxp3^{lo} non-suppressive T cells were increased in patients with SLE as previously reported (Figure 3A). By focusing on Th1 markers such as T-bet, IFN-γ, we found that T-bet IFN-γ CD45RA Foxp3^{lo} non-suppressive T cells were increased, while T-bet IFN-γ
FIGURE 5 | Inhibition of fatty acid synthesis suppressed IFN-γ production and increased Foxp3 expression in T-bet+Foxp3+ cells in memory CD4+ T cells in SLE. CD45RA- memory CD4+ T cells from peripheral blood of HDs and patients with SLE were stimulated for 72 h with anti-CD3 Abs and anti-CD28 Abs or with 2DG (3 mM), rapamycin (10 nM), C75 (10 µM) or etmoxir (10 or 50 µM). (A) Expression of Foxp3 and IFN-γ in CD45RA- memory CD4+ T cells from patients with SLE. Representative experiment depicting Foxp3 and IFN-γ expression in SLE samples (upper panel) and histogram of T-bet expression (lower panel) in three independent experiments. (B) Bar graph of the percentage of Foxp3+IFN-γ+ cells among CD45RA-CD4+ cells from HDs and patients with SLE. Data are mean ± SD of three experiments using CD45RA- memory CD4+ cells from each different donors of HDs and SLE patients (paired T test). (C) Representative data of Foxp3 expression gated in T-bet+Foxp3+ cells in CD4+CD45RA- cells from SLE samples in three independent experiments. (D) Concentration and fold change of cytokines by cytometric bead array in HDs and SLE samples. Data are mean ± SD of using CD45RA- memory CD4+ cells from each different donors of HDs and SLE patients (paired T test). *p < 0.05. **p < 0.01. ***p < 0.001. ****p < 0.0001. n.s., not significant.
Foxp3hiCD45RA− activated-Treg cells were decreased (Figures 3B, C), and the imbalance of these subsets was caused by enhanced fatty acid synthesis (Figures 5B, C).

Although the mTOR signaling inhibitors, including rapamycin, have been reported to be important metabolic control drugs in SLE patients, it has limited effectiveness (50). Our study demonstrated that, unlike rapamycin, 2DG induced IFN-γ non-producing T-bet+Foxp3hi activated-Treg cells differentiation and IL-2 production. In this regard, previous studies reported that a decrease in serum IL-2 level in SLE patients is associated with inhibition of Treg function with consequent enhancement of inflammatory pathology (51, 52). In fact, previous studies showed that administration of a small amount of soluble IL-2 was associated with an increase in Treg cells with a resultant control of SLE disease activity (53). Evidence suggests that the primary cells that produce IL-2 are activated Th cells (54, 55). Our study demonstrated that 2DG induced the production of IL-2 from memory CD4+ cells in patients with SLE (Figure 5D), suggesting that 2DG does not only correct the abnormality of Th1 subsets through the control of abnormal cell metabolism but also improve the pathological status of SLE through the induction of IL-2 production.

Limitations of this study were that a limited number of memory CD4+ T cells can be isolated from the peripheral blood in patients with SLE, and therefore, detailed analysis of the mechanisms occurring in the memory CD4+ T cells derived from the patients was unfeasible. Furthermore, the annual incidence of SLE without treatments for the disease is too limited to allow us to perform these studies.

Taken together, SLE patients exhibited IFN-γ overproduction by Th1 cells and subset imbalance of these cells, suggesting the involvement of Th1 cells in SLE pathology such as treatment resistance. Metabolic regulators, particularly fatty acid synthesis inhibitors, may be therapeutically beneficial in SLE by correcting these abnormalities.

DATA AVAILABILITY STATEMENT

All data generated or analyzed during this study are included in this published article (and its supplementary information files).

REFERENCES

1. Baechler EC, Bhatiwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA (2003) 100:2610–15. doi: 10.1073/pnas.0337679100

2. Chiche L, Jourde-Chiche N, Whalen E, Presnell S, Gersuk V, Dang K, et al. Modulatory transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol (2014) 66:1583–95. doi: 10.1002/art.38628

3. Tsokos GC. Syst Lupus Erythematosus N Engl J Med (2011) 365:2110–21. doi: 10.1056/NEJMra1100359

4. Akahoshi M, Nakashima H, Tanaka Y, Kohsaka T, Nagano S, Ohgami E, et al. Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheumatol (1999) 42:1644–8. doi: 10.1002/1529-0131(199908)42:8<1644::AID-ANR2>3.0.CO;2-L

5. Harigai M, Kawamoto M, Hara M, Kubota T, Kamatani N, Miyasaka N. Excessive Production of IFN-γ in Patients with Systemic Lupus Erythematosus and Its Contribution to Induction of B Lymphocyte Stimulator/B Cell-Activating Factor/TNF Ligand Superfamily-13B. J Immunol (2008) 181(3):2211–9. doi: 10.4049/jimmunol.181.3.2211

6. Caielli S, Vega DT, Balasubramanian P, Athale S, Domic B, Murat E, et al. A CD4+ T cell population expanded in lupus blood provides B cell help through interleukin-10 and succinate. Nat Med (2019) 25:75–81. doi: 10.1038/s41591-018-0254-9

7. Rao DA, Gurish MF, Marshall JL, Slowikowski K, Fonseka CY, Liu Y, et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature (2017) 542:110–4. doi: 10.1038/nature20810

8. Wang S, Wang J, Kumar V, Karnell JL, Naiman B, Gross PS, et al. IL-21 drives expansion and plasma cell differentiation of autoreactive CD11c+ “T-bet”+ B cells in SLE. Nat Commun (2018) 9:1758. doi: 10.1038/s41467-018-03750-7

9. Jenks SA, Cashman KS, Zamaquero E, Marigorta UM, Patel AV, Wang X, et al. Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Human Ethics Review Committee of the University of Occupational and Environmental Health, Japan, and each subject provided a signed consent form (H29-045). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

SI wrote the manuscript and designed the experiments. SI, MZ, HH, GT, MH, YM, NO, YS-K, YaT, HM, MU, AN, SN, and KS performed the experiments. SI, MZ, HH, YM, and NO analyzed the data. YoT supervised the project. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported in part by JSPS KAKENHI grant number #JP16K09928 and the University of Occupational and Environmental Health, Japan, through UOEH Grant for Advanced Research (#H29-903 and #H30-905).

ACKNOWLEDGMENT

The authors thank the patients and healthy volunteers for their cooperation and consent to participate in the study. The authors also thank Ms. N. Sakaguchi, T. Umata, and K. Hara for the excellent technical assistance (Umata Toshiyuki RI Center, Sakaguchi Narumi, Hara Kyoko Shared-Use Research Center).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2020.593103/full#supplementary-material

This page has been typeset from the electronic copy of this article.
Contribute to Pathogenic Responses in Systemic Lupus Erythematosus. *Immunity* (2018) 49:725–39. doi: 10.1016/j.immuni.2018.08.015

Rubtsov K, Rubtsov AV, Thurman JM, Menonna JM, Kappler JW, Marrack P. B cells expressing the transcription factor T-bet drive lupus-like autoimmunity. *J Clin Invest* (2017) 127:1392–404. doi: 10.1172/JCI91250

Wu C, Fu Q, Guo Q, Chen S, Goswami S, Sun S, et al. Lupus-associated atypical memory B cells are mTORC1-hyperactivated and functionally dysregulated. *Ann Rheum Dis* (2019) 78:1090–100. doi: 10.1136/annrheumdis-2019-215039

Bocharnikov AV, Keegan J, Wadleche VS, Cao Y, Fonseka CY, Wang G, et al. The chromatin-modifying enzyme Ezh2 is critical for the maintenance of FoxP3 transcription factor. *Nature* (2009) 30:899–901. doi: 10.1016/j.immuni.2009.03.019

T-cell metabolism reverses lupus. *Sci Transl Med* (2015) 7:274ra18. doi: 10.1126/scitranslmed.aad0835

Berod L, Friedrich C, Nandan A, Freitag J, Hagemann S, Harmollo K, et al. De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. *Nat Med* (2014) 20:1327–33. doi: 10.1038/nm.3704

Morel L. Immunometabolism in systemic lupus erythematosus. *Nat Rev Rheumatol* (2017) 13:280–90. doi: 10.1038/nrrheum.2017.43

Sharabi A, Tsokos GC. T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy. *Nat Rev Rheumatol* (2020) 16:100–12. doi: 10.1038/s41584-019-0356-x

Zeng H, Chi H. mTOR signaling in the differentiation and function of regulatory and effector T cells. *Curr Opin Immunol* (2017) 46:103–11. doi: 10.1016/j.coi.2017.04.005

Pollizi KN, Powell JD. Regulation of T cells by mTOR: the known knowns and the known unknowns. *Trends Immunol* (2015) 36:13–20. doi: 10.1016/j.it.2014.11.005

Shi LZ, Wang R, Huang G, Vogel P, Neale G, Green DR, et al. HIIF-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. *J Exp Med* (2011) 208:1367–76. doi: 10.1084/jem.20110278

Gerriets VA, Kishston RJ, Nichols AG, Macintyre AN, Inoue M, Iklayeva O, et al. Metabolic programming and PDH1K1 control CD4+ T cell subsets and inflammation. *J Clin Invest* (2015) 125:194–207. doi: 10.1172/JCI76012

Newton R, Priyadarsinhi B, Turka LA. Immunometabolism of regulatory T cells. *Nat Immunol* (2016) 17:618–25. doi: 10.1038/nli.3466

Powell JD. Pollizi KN, Heikamp ER, Horton MR. Regulation of immune responses by mTOR. *Annu Rev Immunol* (2012) 30:39–68. doi: 10.1146/annurev-immunol-020711-075024

Park Y, Jin HS, Lopez J, Elly C, Kim G, Muriel M, et al. TSC1 regulates the balance between effector and regulatory T cells. *J Clin Immunol* (2013) 123:5165–78. doi: 10.1016/j.jci.2017f9751

Shresta S, Yang K, Guy C, Vogel P, Neale G, Chi H. Treg cells require the phosphatase Pten to restrain TH1 and THF cell responses. *Nat Immunol* (2015) 16:178–87. doi: 10.1038/nli.3076

Zeng H, Yang K, Cloer C, Neale G, Vogel P, Chi H. mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. *Nature* (2013) 499:485–90. doi: 10.1038/nature12297

Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urbahl KB, Campbell DJ. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. *Nat Immunol* (2009) 10:595–602. doi: 10.1038/ni.1731

Koch MA, Thomas KR, Perdue NR, Smigel KS, Srivastava S, Campbell DJ. T-bet(-) T cells undergo abortive Th1 cell differentiation due to impaired expression of IL-12 receptor β2. *Immunity* (2012) 37:501–10. doi: 10.1016/j.immuni.2012.05.031

Yu F, Sharma S, Edwards J, Feigenbaum L, Zhu J. Dynamic expression of transcription factors Blimp-1 and IRF4 jointly control the differentiation and transcription factors T-bet and GATA-3 by regulatory T cells maintains immunotolerance. *Nat Immunol* (2015) 16:197–206. doi: 10.1038/nli.3053

Tan TG, Mathis D, Benoist C. Regulatory T cells in protection from autoimmune diabetes. *Proc Natl Acad Sci USA* (2016) 113:1403–08. doi: 10.1073/pnas.1617101113

McPherson RC, Turner DG, Mair I, O’Connor RA. Anderton SM. T-bet Expression by Foxp3+ T Regulatory Cells is Not Essential for Their Suppressive Function in CNS Autoimmune Disease or Colitis. *Front Immunol* (2015) 6:699. doi: 10.3389/fimmu.2015.00669

Suen JL, Chiang BL. CD4+ FoxP3+ regulatory T-cells in human systemic lupus erythematosus. *J Formos Med Assoc* (2012) Sep 11(9):465–70. doi: 10.1016/j.jfma.2012.05.013

Li W, Deng C, Yang H, Wang G. The Regulatory T Cell in Active Systemic Lupus Erythematosus Patients: A Systemic Review and Meta-Analysis. *Front Immunol* (2019) 10:159. doi: 10.3389/fimmu.2019.00159

Perl A. Activation of mTOR ( mechanistic target of rapamycin) in rheumatic diseases. *Nat Rev Rheumatol* (2016) 12:169–82. doi: 10.1038/nrrheum.2015.172

Humbich JY, Morbach H, Undeutsch R, Enghard P, Rosenberger S, Weigert O, et al. Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. *Proc Natl Acad Sci USA* (2010) 107:2094–9. doi: 10.1073/pnas.0903158107

von Spee-Mayer C, Siegent E, Abdirama D, Rose A, Klaus A, Alexander T, et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in
patients with systemic lupus erythematosus. *Ann Rheum Dis* (2016) 75:1407–15. doi: 10.1136/annrheumdis-2015-207776

53. He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. *Nat Med* (2016) 22:991–3. doi: 10.1038/nm.4148

54. Malek TR. The biology of interleukin-2. *Annu Rev Immunol* (2008) 26:453–79. doi: 10.1146/annurev.immunol.26.021607.090357

55. Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. *Nat Rev Immunol* (2012) 12:180–90. doi: 10.1038/nri3156

**Conflict of Interest:** KS is an employee of Mitsubishi Tanabe Pharma. SN has received speaking fees from Bristol Myers, Sanofi, Abbvie, Eisai, Eli Lilly, Chugai, Pfizer, Takeda, and also research grants from Mitsubishi Tanabe, Novartis, and MSD. YT received research grants from Mitsubishi Tanabe, Takeda, Daiichi-Sankyo, Chugai, Bristol-Myers, MSD, Astellas, Abbvie, and Eisai.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2020 Iwata, Zhang, Hao, Trimova, Haimme, Miyazaki, Ohkubo, Satoh Kanda, Todoroki, Miyata, Ueno, Nagayasu, Nakayamada, Sakata and Tanaka. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*